Lack of efficacy of high-dose intravenous immunoglobulin treatment of severe thrombocytopenia in patients with secondary dengue virus infection

Efren M. Dimaano, Mariko Saito, Shoko Honda, Edna A. Miranda, Maria T.G. Alonzo, Myra D. Valerio, Cynthia A. Mapua, Shingo Inoue, Atsushi Kumaori, Ronald Matias, Filipinas F. Natividad, Kazunori Oishi

Research output: Contribution to journalArticlepeer-review

45 Citations (Scopus)

Abstract

Because most cases of secondary dengue virus infection are associated with an increased level of platelet-associated IgG, a high dose of intravenous immunoglobulin (IVIG) may have an effect on the development of severe thrombocytopenia in this disease. A randomized, controlled study was conducted with two treatment groups consisting of a treatment (IVIG) group (n = 15) and a non-treatment (non-IVIG) group (n = 16) to determine whether a high dose of IVIG is effective in hastening the recovery from thrombocytopenia in patients with secondary dengue virus infection. No significant difference was found in the baseline demographic data between the two groups. No adverse effect of IVIG was observed, but no effect in hastening the recovery of platelet counts was found in patients with secondary dengue infections. The lack of efficacy of IVIG suggests that platelet clearance by macrophages through Fc γ receptors is not a primary mechanism in this disease.

Original languageEnglish
Pages (from-to)1135-1138
Number of pages4
JournalAmerican Journal of Tropical Medicine and Hygiene
Volume77
Issue number6
DOIs
Publication statusPublished - 2007 Dec
Externally publishedYes

ASJC Scopus subject areas

  • Parasitology
  • Virology
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Lack of efficacy of high-dose intravenous immunoglobulin treatment of severe thrombocytopenia in patients with secondary dengue virus infection'. Together they form a unique fingerprint.

Cite this